3 Biopharmas on Buyout Watch
22/8 14:00
The pharmaceutical merger and acquisition (M&A) scene is heating up. Speaking to this point, Pfizer recently doled out $5.4 billion to acquire Global Blood Therapeutics for its sickle cell disease assets. Amgen spent $3.7 billion on a deal earlier this month for ChemoCentryx...